|
Founded in 1994, Genesis Research
and Development Corporation is a New Zealand based biotechnology
company. It is committed to the building of a broad genomic platform for
the development of innovative products in biotechnology. Genesis
partners with industry leaders to develop products that have global
market potential through the mining of its extensive EST databases.
The Health Division focuses on the immune system and has two programmes
in Phase II clinical studies for the treatment of psoriasis and atopic
dermatitis (eczema), with additional programmes for cancer and other
indications in pre-clinical development. The patented BioStore solutions
for storage of tissues and living cells are also in pre-clinical
development. Collaborations are maintained with Amgen Inc. (Nasdaq:
AMGN), Corixa Corporation (Nasdaq: CRXA), SR Pharma (LSE: SPA), Jurox
Pty Ltd, and EvoGenix Pty Ltd. The company has an extensive
patent portfolio.
AgriGenesis Biosciences Ltd is a wholly owned subsidiary of
Genesis Research and Development Corporation Ltd. It focuses on key cell
signalling genes – novel hormones and transcription factors – to control
commercial traits including growth rates and wood fibre quality in
trees, nutritional content of forage grasses, flowering control and
stress tolerance. It has an extensive patent portfolio and research
collaborations with ArborGen, LLC, Wrightson Ltd (NZX: WRI),
HortResearch, AgResearch and Landcare. AgriGenesis has long-term grants
from the Foundation for Research Science and Technology and Technology
NZ, and is also undertaking significant unpartnered research programmes
in novel plant hormones. |
